New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
05:05 EDTONXX, BAYRYBayer, Onyx announce Phase 3 DECISION trial of Nexavar meets primary endpoint
Bayer HealthCare Pharmaceuticals (BAYRY) and Onyx Pharmaceuticals (ONXX) announced that a Phase 3 trial of Nexavar tablets in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. Adverse events were generally consistent with the known profile for Nexavar. Data from this study are expected to be presented at an upcoming medical meeting.
News For BAYRY;ONXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
11:13 EDTBAYRYBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
10:04 EDTBAYRYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:31 EDTBAYRYBayer downgraded to Neutral from Buy at UBS
Subscribe for More Information
March 25, 2015
07:17 EDTBAYRYSociety for Reproductive Investigation to hold scientific meeting
62nd Annual Scientific Meeting: SRI 2015 is being held in San Francisco on March 25-28.
March 20, 2015
07:41 EDTBAYRYAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use